Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

Oriahnn™ comes packaged as a daily oral medication giving women the options to avoid surgery, procedure, or a birth control method.

First approval in 16 years for mesothelioma, a type of cancer caused by inhaling asbestos fibers SILVER SPRING, Md., Oct. 2, 2020 /PRNewswire/ -- Today, the U.S. Food...

She is sick of using birth control, but now is not the right time to get pregnant. The “pull and pray” method is too...

The first antiviral nasal spray in the United States. Nomovid™ Nasal Spray will be easy-to-use, low-cost and can be quickly made available over-the-counter for consumers.

Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.

The three botanicals are synergistically blended with a unique proprietary technology to provide fast relief of acute musculoskeletal pain.

SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

The FDA has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy in children and adults

the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults